Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma

NCT00065351 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
222
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Celgene